Dr. Reddy's Launches India's First DCGI-Approved Semaglutide Injection 'Obeda®' for Type 2 Diabetes
Dr. Reddy's launched 'Obeda®', India's first DCGI-approved generic semaglutide injection for Type 2 Diabetes. It demonstrated non-inferior efficacy and safety in Phase III trials. Available in 2mg and 4mg strengths at ₹4,200/month, it aims to improve access to advanced therapies.
The launch of a novel drug, especially one that is a first in its category for the Indian market and addresses a widespread condition like Type 2 Diabetes, is expected to have a significant impact on the company's market presence, revenue, and patient reach.
The launch of a new, first-of-its-kind drug that addresses a significant health issue like Type 2 Diabetes, coupled with positive clinical trial results and a commitment to patient access, indicates a positive development for the company.
Dr. Reddy's Laboratories Limited has announced the launch of India's first DCGI-approved semaglutide injection, 'Obeda®', for the management of type 2 diabetes. This launch marks Dr. Reddy's entry into the GLP-1 receptor agonists therapy space, aiming to expand access to advanced treatments in India.
In a Phase III clinical study involving 312 participants, Obeda® demonstrated non-inferior efficacy and a comparable safety profile to the innovator drug, showing similar glycaemic reduction. The drug, developed entirely in-house for both API and formulation, underscores the company's expertise in complex product development and peptide science.
Obeda® is available in 2 mg and 4 mg strengths, offered in a pre-filled, disposable pen for once-a-week subcutaneous administration. Each pen provides a minimum of four weekly doses, with the patient cost set at ₹4,200 per month for both strengths. The company also plans to introduce generic semaglutide in several other countries, subject to regulatory approvals.
To support patients, Dr. Reddy's has developed 'SemaKare™', a comprehensive patient support program offering onboarding guidance, injection training, and adherence monitoring. Additionally, the company aims to establish metabolic centers of excellence across India to advance diabetes and metabolic disorder treatment through HCP education and patient empowerment initiatives.
What to do with a filing like this
Dr. Reddy's Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under product launches. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Reddy's Laboratories Limited. Read the original for the full detail.